TransMedics Group (NASDAQ:TMDX) Trading Down 5.2% - Here's What Happened

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report)'s stock price fell 5.2% on Friday . The stock traded as low as $118.83 and last traded at $118.23. 229,037 shares traded hands during trading, a decline of 83% from the average session volume of 1,364,356 shares. The stock had previously closed at $124.78.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Piper Sandler reaffirmed an "overweight" rating and issued a $145.00 target price (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Finally, Oppenheimer raised their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, TransMedics Group has an average rating of "Moderate Buy" and a consensus target price of $127.33.

TransMedics Group Trading Down 9.9%

The firm has a market cap of $3.80 billion, a P/E ratio of 82.69 and a beta of 2.06. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10. The firm has a 50 day simple moving average of $125.49 and a 200 day simple moving average of $90.46.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The business had revenue of $143.54 million during the quarter, compared to analysts' expectations of $123.39 million. During the same period in the previous year, the business earned $0.35 earnings per share. The firm's revenue was up 48.2% on a year-over-year basis. On average, equities research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the transaction, the insider owned 13,955 shares of the company's stock, valued at $1,950,909. This represents a 4.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director David Weill sold 732 shares of the company's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the completion of the transaction, the director owned 12,134 shares of the company's stock, valued at $1,503,159.92. This trade represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,418 shares of company stock worth $1,512,613 in the last quarter. 7.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in TransMedics Group by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock worth $226,700,000 after purchasing an additional 40,860 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of TransMedics Group by 244.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock worth $209,448,000 after buying an additional 2,209,996 shares during the period. FIL Ltd increased its stake in shares of TransMedics Group by 28.0% in the 4th quarter. FIL Ltd now owns 1,000,358 shares of the company's stock worth $62,372,000 after acquiring an additional 218,961 shares in the last quarter. Braidwell LP bought a new stake in TransMedics Group during the fourth quarter worth about $57,493,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in TransMedics Group by 16.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock worth $56,307,000 after purchasing an additional 128,474 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.